Sukriti Pruthi¹, Archana Chauhan¹, Markanday Sharma²* and Bhupesh Guleria³

¹Junior Resident, Department of Psychiatry, Armed Forces Medical College, Pune, India
²Assistant Professor, Department of Psychiatry, Armed Forces Medical College, Pune, India
³Associate Professor and Medical Oncologist, Department of Internal Medicine, Armed Forces Medical College, Pune, India
²Assistant Professor, Department of Psychiatry, Armed Forces Medical College, Pune, India

*Corresponding Author: Markanday Sharma, Assistant Professor, Department of Psychiatry, Armed Forces Medical College, Pune, India.

Received: October 10, 2023; Published: December 13, 2023

Abstract

The second most common haematological malignancy, Multiple Myeloma (MM), is caused by the clonal proliferation of malignant plasma cells. With little side effects, Bortezomib, first proteasome inhibitor, increased response rates and overall survival in newly diagnosed and recurring patients of MM. While corticosteroids are known to result in several psychiatric manifestations, there are only a few reported cases of mental illnesses caused by Bortezomib accounted for in the literature. This article describes a 68-year-old man who has multiple myeloma. He has been stated as experiencing manic symptoms and is currently undergoing regular treatment with Bortezomib, Dexamethasone, and Cyclophosphamide. After the second cycle, there was a noticeable increase in irritation, which subsequently escalated to reflect symptoms of decreased sleep, aggressive conduct, spending spree, and increased energy. He was diagnosed as a case of Drug induced (Bortezomib) Mania. Chemotherapy was abruptly discontinued and treated with Tab Olanzapine 10 mg/day. The symptoms were seen to gradually improve, and alternative chemotherapy was intended to resume soon after. The case report highlights high index of suspicion of psychiatric complications, timely detection and immediately stopping related drug (Bortezomib) are key steps in management.

Keywords: Mania; Bortezomib; Multiple Myeloma

References

1. Rajkumar SV. “Multiple myeloma: 2022 update on diagnosis, risk stratification, and management”. American Journal of Hematology (2022).
2. Jiang H., et al. “Mania in a Patient with Multiple Myeloma After Using Bortezomib”. Journal of Medical Cases 12 (2014): 627-630.
3. Hjorth M., et al. “Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study”. European Journal of Haematology 6 (2012): 485-496.
4. Palumbo A., et al. “Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma”. Annals of Oncology 6 (2008): 1160-1165.
5. Field-Smith A., et al. “Bortezomib (Velcade^TM) in the Treatment of Multiple Myeloma”. Therapeutics and Clinical Risk Management 3 (2006): 271-279.
6. Jasani R., et al. “Corticosteroid-Induced Mania After Previous Tolerance of Higher Doses”. Cureus9 (2008): e17719.
7. Genis B and Cosar B. “Mania Associated with the Use of Bortezomib and Dexamethasone”. Turkish Journal of Psychiatry (2018).
8. Kelly K., et al. “Bortezomib-induced reversible posterior leucoencephalopathy syndrome”. British Journal of Haematology 5 (2008): 566-566.

Citation

Citation: Markanday Sharma., et al. “Bortezomib Induced Mania: An Unrivalled Case Report". Acta Scientific Neurology 7.1 (2024): 27-29.

Copyright

Copyright: © 2024 Markanday Sharma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.